BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer

In spite of the fact that they occur at high rates, the clinical responses of BRAF(V600) mutant metastatic melanoma to BRAF inhibitors are usually short-lasting, with most cases progressing within less than 8 mo. Immunomodulatory strategies initiated after progression have recently been reported to...

Descripción completa

Detalles Bibliográficos
Autores principales: Donia, Marco, Fagone, Paolo, Nicoletti, Ferdinando, Andersen, Rikke Sick, Høgdall, Estrid, Straten, Per thor, Andersen, Mads Hald, Svane, Inge Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525603/
https://www.ncbi.nlm.nih.gov/pubmed/23264894
http://dx.doi.org/10.4161/onci.21940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525603/
https://www.ncbi.nlm.nih.gov/pubmed/23264894
http://dx.doi.org/10.4161/onci.21940

Ejemplares similares